糖尿病予防と治療のエビデンス

出版社: 中山書店
著者:
発行日: 2012-05-30
分野: 臨床医学:内科  >  糖尿病
ISBN: 9784521733807
電子書籍版: 2012-05-30 (初版第1刷)
書籍・雑誌
≪全国送料無料でお届け≫
発送目安:8~14営業日

7,480 円(税込)

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

7,480 円(税込)

商品紹介

患者数の増加により,世界レベルでも問題となっている糖尿病について,診療の根拠となる国内外の臨床研究・疫学研究を簡潔に解説。病態・検査・治療法など,糖尿病のあらゆる側面から丁寧にレビューし,克服すべき「糖尿病」の本質を見極めるための有益な情報が多く盛り込まれた,臨床家必携の書。

目次

  • 糖尿病予防と治療のエビデンス

    ―目次―

    1章 エビデンスとは何か?
    2章 糖尿病の疫学
    3章 糖尿病の成因と病態に関するエビデンス
    4章 糖尿病の検査―診断・合併症予測因子としてのエビデンス
    5章 糖尿病の予防
    6章 糖尿病の治療

おすすめ商品

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1章 エビデンスとは何か ?

P.15 掲載の参考文献
P.21 掲載の参考文献
1) University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes I. Design, methods and baseline results, II. Mortality results. Diabetes 1970 ; 19 (Suppl 2) : 747-83, 789-830.
2) University Group Diabetes Program. A study of the effects of hypoglycemia agents on vascular complications in patients with adult-onset diabetes. VI. Supplementary report on nonfatal events in patients treated with tolbutamide. Diabetes 1976 ; 25 : 1129-53.
3) University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. V. Evaluation of phenformin therapy. Diabetes 1974 ; 24 (Suppl 1) : 65-184.
4) Edwards CC. Oral hypoglycemic agents. Report of the food and drug administration. Diabetes 1970 ; 19 (Suppl 2) : viii-ix.
5) Report of the Committee for the assessment of Biometric Aspects of Controlled Trials of Hypoglycemic Agents. JAMA 1975 ; 231 : 583-608.
8) Tattersall R. Diabetes : The Biography. Oxford Univ Press ; 2009. pp.131-5.
9) 日本糖尿病学会理事会. トルブタマイドに関する最近の問題について. 糖尿病 1970 ; 13 : 417.
10) 平田幸正. 糖尿病経口薬の意義とその問題点. 糖尿病学の進歩. 第10集. 診断と治療社 ; 1976, pp.191-202.
・ 小坂樹徳ほか. 経口糖尿病薬の功罪 (パネル). 日本糖尿病学会編. 糖尿病学の進歩. 第5集. 診断と治療社 ; 1971. pp.205-31.

2章 糖尿病の疫学

P.30 掲載の参考文献
1) International Diabetes Federation. Diabetes Atlas, 5th ed. 2011.
2) Patterson CC, et al ; EURODIAB Study Group. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20 : a multicentre prospective registration study. Lancet 2009 ; 373 : 2027-33.
P.39 掲載の参考文献
2) IDF Diabetes atlas, 5th ed. cInternational Diabetes Federation, 2011. http://www.diabetesatlas.com/
4) Wild S, et al. Global Burden of Diabetes Mellitus in the Year 2000. http://www.who.int/healthinfo/statistics/bod_diabetes.pdf
6) 厚生労働省. 平成19年国民健康・栄養調査報告. http://www.mhlw.go.jp/houdou/2008/12/h1225-5.html
7) 厚生労働省. 平成21年国民健康・栄養調査報告. p.102. http://www.mhlw.go.jp/bunya/kenkou/eiyou/dl/h21-houkoku-01.pdf
10) Kato M, et al. Fasting plasma glucose and incidence of diabetes-implication for the threshold for impaired fasting glucose : results from the population-based Omiya MA cohort study. J Atheroscler Thromb 2009 ; 16 : 857-61.
11) 健康日本21. 健康日本21企画検討会・健康日本21計画策定検討会報告書. 健康・体力づくり事業財団 ; 2001. pp.137-145.
P.46 掲載の参考文献
5) 猪股茂樹ほか. 糖尿病性腎症の新しい診断基準. 糖尿病 2005 ; 48 : 757-9.
P.52 掲載の参考文献
1) 船津英陽ほか. 糖尿病眼合併症の有病率と全身因子. 日眼会誌 1993 ; 97 : 947-54.
2) 高橋義彦, 野田光彦. 糖尿病網膜症の疫学とリスクファクター. 内分泌・糖尿病科 2009 ; 28 : 188-95.
3) 安田美穂 : 久山町研究. あたらしい眼科 2011 ; 28 : 25-9.
4) 川崎良. 糖尿病網膜症-舟形町スタディ. 日本の眼科 2008 ; 79 : 1697-701.
5) 川崎良. 世界の疫学研究-先進国編. あたらしい眼科 2011 ; 28 : 41-7.
6) Sone H, et al ; Japan Diabetes Complications Study Group. Long-term lifestyle intervention lowers the incidence of stroke in Japanese patients with type 2 diabetes : a nationwide multicentre randomised controlled trial (the Japan Diabetes Complications Study). Diabetologia 2010 ; 53 : 419-28.
P.60 掲載の参考文献
3) 糖尿病性神経障害を考える会. 糖尿病性多発神経障害の簡易診断基準. 末梢神経 1998 ; 9 : 137-40.
4) 佐藤譲ほか. 糖尿病神経障害の発症頻度と臨床診断におけるアキレス腱反射の意義-東北地方15,000人の実態調査. 糖尿病 2007 ; 50 : 799-806.
5) Shaw JE, Zimmet PZ. The epidemiology of diabetic neuropathy. Diabetes Rev 1999 ; 7 : 245-52.
6) 糖尿病性神経障害を考える会. 簡易診断基準をもとにした糖尿病性多発神経障害の病期分類の公表にあたって. Peripheral Nerve 2010 ; 21 : 372-3.
P.65 掲載の参考文献
1) 内村功, 渥美義仁監訳. インターナショナル・コンセンサス糖尿病足病変. 医歯薬出版 ; 2000.
2) Al-Mahroos F, Al-Roomi K. Diabetic neuropathy, foot ulceration, peripheral vascular disease and potential risk factors among patients with diabetes in Bahrain : a nationwide primary care diabetes clinic-based study. Ann Saudi Med 2007 ; 27 : 25-31.
4) Abbott CA, et al. The North-West Diabetes Foot Care Study : incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. Diabet Med 2002 ; 19 : 377-84.
9) Reiber GE. The epidemiology of diabetic foot problems. Diabet Med 1996 ; 13 (Suppl 1) : S6-11.
18) Meijer JW, et al. Quality of life in patients with diabetic foot ulcers. Disabil Rehabil 2001 ; 23 : 336-40.
20) Brod M. Quality of life issues in patients with diabetes and lower extremity ulcers : patients and care givers. Qual Life Res 1998 ; 7 : 365-72.
26) Holzer SE, et al. Costs and duration of care for lower extremity ulcers in patients with diabetes. Clin Ther 1998 ; 20 : 169-81.
38) 厚生労働省. 平成19年国民健康・栄養調査結果の概要. Retrieved May 19, 2011. (http://www.mhlw.go.jp/houdou/2008/12/h1225-5a.html)
P.72 掲載の参考文献
9) Glucose tolerance and mortality : comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology : Collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999 ; 354 : 617-21.
P.80 掲載の参考文献
P.86 掲載の参考文献
P.91 掲載の参考文献
1) 健康日本21ホームページ. http://www.kenkounippon21.gr.jp/
3) 糖尿病ネットワークホームページ. http://www.dm-net.co.jp/calendar/2011/011746.php
5) 糖尿病における失明, 歯周病, 腎症, 大血管合併症などの実態把握とその治療に関するデータベース構築による大規模前向き研究. 平成21年度~22年度総合研究報告書 <厚生労働科学研究費補助金 循環器疾患・糖尿病等生活習慣病対策総合研究事業>, 研究代表者田嶼尚子. 2011.

3章 糖尿病の成因と病態に関するエビデンス

P.99 掲載の参考文献
2) 山根公則ほか. 日本人と環境因子 : 日本人と在米日系人の生活習慣病-糖尿病, 高脂血症, 動脈硬化. 最新医学 2002 ; 57 (3月増刊号) : 689-98.
4) 清野裕. 糖尿病の新しい概念. 最新医学 1995 ; 50 (臨増) : 639-45.
6) DeFronzo RA, Abdul-Ghani MA. Preservation of β-cell function : the key to Diabetes prevention. J Clin Endocrinol Metab 2011 ; 96 : 2354-66.
13) Hojberg PV, et al. Four weeks of near-normalization of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic peptide in patients with type 2 diabetes. Diabetologia 2009 ; 52 : 199-207.
P.106 掲載の参考文献
1) Fukusima M, et al. Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract 2004 ; 66 (Suppl 1) : S37-43.
4) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 ; 352 : 854-65.
P.112 掲載の参考文献
3) Knowler WC, et al ; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002 ; 346 : 393-403.
6) Sakane N, et al. Prevention of type 2 diabetes in a primary healthcare setting : three-year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health 2011 ; 11 : 40.
9) 厚生労働省健康科学総合研究事業. 糖尿病発症高危険群におけるインスリン抵抗性とその生活習慣基盤に関する多施設共同追跡調査-介入対象としての内臓肥満の意義の確立 (主任研究者松澤佑次) 総合研究報告書. 2001.
P.120 掲載の参考文献
1) メタボリックシンドローム診断基準検討委員会. メタボリックシンドロームの定義と診断基準. 日本内科学会雑誌 2005 ; 94 : 794-809.
3) Hiuge-Shimizu A, et al. Absolute value of visceral fat area measured on computed tomography scans and obesity-related cardiovascular risk factors in large-scale Japanese general population (the VACATION-J study). Ann Med 2012 ; 44 : 82-92.

4章 糖尿病の検査 - 診断・合併症予測因子としてのエビデンス

P.129 掲載の参考文献
1) 葛谷健. 糖尿病の新しい診断基準日本および世界の糖尿病の診断基準の変遷-2000年まで. 内分泌・糖尿病・代謝内科 2011 ; 32 : 4-9.
2) 葛谷健ほか. 糖尿病の分類と診断基準に関する委員会報告. 糖尿病 1999 ; 42 : 385-404.
4) World Health Organizationa. Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus. Abbreviated Report of a WHO Consultation ; 2011.
5) 清野裕ほか. 糖尿病の分類と診断基準に関する委員会報告. 糖尿病 2010 ; 53 : 450-67.
・ 小坂樹徳, 門脇 孝. 糖尿病診療のあゆみと展望. 文光堂 ; 2007.
P.135 掲載の参考文献
1) 清野裕ほか. 糖尿病の分類と診断基準に関する委員会報告. 糖尿病 2010 ; 53 : 450-67.
2) 門脇孝ほか. 糖尿病・糖代謝異常に関する診断基準検討委員会報告-空腹時血糖値の正常域に関する新区分. 糖尿病 2008 ; 51 : 281-3.
3) 日本糖尿病学会編. 治療目標とコントロール指標. 糖尿病治療ガイド 2010. 文光堂 ; 2010. pp.24-5.
P.140 掲載の参考文献
P.146 掲載の参考文献
8) Lu L, et al. Association of serum levels of glycated albumin, C-reactive protein and tumor necrosis factor-α with the severity of coronary artery disease and renal impairment in patients with type 2 diabetes mellitus. Clin Biochem 2007 ; 40 : 810-6.
P.152 掲載の参考文献
P.158 掲載の参考文献
7) 西村理明. CGM-持続血糖モニターが切り開く世界. 改訂版. 医薬ジャーナル社 ; 2011.

5章 糖尿病の予防

P.166 掲載の参考文献
1) Knowler WC, et al ; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002 ; 346 : 393-403.
2) Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP) : description of lifestyle intervention. Diabetes Care 2002 ; 25 : 2165-71.
4) Look AHEAD Research Group, et al. The Look AHEAD study : a description of the lifestyle intervention and the evidence supporting it. Obesity 2006 ; 14 : 737-52.
P.174 掲載の参考文献
1) 伊藤千賀子ほか. 血糖の指標と糖尿病発症. medicina 2010 ; 47 : 1910-3.
2) Heianza Y, et al. HbA1c 5・7-6・4% and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3) : a longitudinal cohort study. Lancet 2011 ; 378 : 147-55.
5) Mizoue T, et al. Dietary patterns and glucose tolerance abnormalities in Japanese men. J Nutr 2006 ; 136 : 1352-8.
8) 石田さくらこほか. 生活習慣介入による糖尿病一次予防 (The Diabetes Prevention Program of Hiroshima ; DPPH). 糖尿病 2004 ; 47 : 707-13.
9) Sakane N, et al. Prevention of type 2 diabetes in a primary healthcare setting : three-year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health 2011 ; 11 : 40.
11) 坂根直樹ほか. 2型糖尿病発症予防のための介入試験-J-DOIT1. Diabetes Frontier 2008 ; 19 : 638-42.
P.180 掲載の参考文献
1) Knowler WC, et al ; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002 ; 346 : 393-403.
2) Knowler WC, et al ; Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005 ; 54 : 1150-6.
3) Buchanan TA, et al. Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002 ; 51 : 2796-803.
4) Xiang AH, et al. Effect of pioglitazone on pancreatic β-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 2006 ; 55 : 517-22.
P.186 掲載の参考文献
P.194 掲載の参考文献
3) Schernthaner G, et al ; Quartet [corrected] Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus : a doubleblind, randomized trial. J Clin Endocrinol Metab 2004 ; 89 : 6068-76.
5) Knowler WC, et al ; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002 ; 346 : 393-403.
6) Nathan DM, et al ; American Diabetes Association ; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes : a consensus algorithm for the initiation and adjustment of therapy : a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009 ; 32 : 193-203.
9) 加来浩平ほか. 2型糖尿病患者におけるメトホルミンの使用実態に関する観察研究 (MORE study). 糖尿病 2006 ; 49 : 325-31.
P.201 掲載の参考文献
1) NAVIGATOR Study Group, et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010 ; 362 : 1463-76.
2) NAVIGATOR Study Group, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010 ; 362 : 1477-90.
P.206 掲載の参考文献
1) Tuomilehto J, et al ; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001 ; 344 : 1343-50.
2) Knowler WC, et al ; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002 ; 346 : 393-403.
3) Sakane N, et al ; Japan Diabetes Prevention Program (JDPP) Research Group. Prevention of type 2 diabetes in a primary healthcare setting : three-year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health 2011 ; 11 : 40.
4) Hernan WH, et al ; Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program. Diabetes Care 2003 ; 26 : 36-47.

6章 糖尿病の治療

P.212 掲載の参考文献
P.220 掲載の参考文献
1) 日本糖尿病学会編. 科学的根拠に基づく糖尿病診療ガイドライン 2010. 南江堂 ; 2010.
5) Institute of Medicine : Dietary Reference Intakes : Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, DC ; National Academies Press, 2002.
7) Gardner CD, et al. Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women : the A TO Z Weight Loss Study : a randomized trial. JAMA 2007 ; 297 : 969-77.
9) American Dietetic Association. Nutrition Recommendation and Interventions for Diabetes. 2008.
P.225 掲載の参考文献
P.233 掲載の参考文献
3) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 ; 352 : 37-53.
8) Action to Control Cardiovascular Risk in Diabetes Study Group, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008 ; 358 : 2545-59.
9) ADVANCE Collaborative Group, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008 ; 358 : 2560-72.
11) ACCORD Study Group, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011 ; 364 : 818-28.
18) Zoungas S, et al ; ADVANCE Collaborative Group. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010 ; 363 : 1410-8.
25) Sone H, et al ; Japan Diabetes Complications Study Group. Long-term lifestyle intervention lowers the incidence of stroke in Japanese patients with type 2 diabetes : a nationwide multicentre randomised controlled trial (the Japan Diabetes Complications Study). Diabetologia 2010 ; 53 : 419-28.
26) Katayama S, et al ; Japan Diabetes Complications Study Group. Low transition rate from normo- and low microalbuminuria to proteinuria in Japanese type 2 diabetic individuals : the Japan Diabetes Complications Study (JDCS). Diabetologia 2011 ; 54 : 1025-31.
27) Kawasaki R, et al ; Japan Diabetes Complications Study Group. Incidence and progression of diabetic retinopathy in Japanese adults with type 2 diabetes : 8 year follow-up study of the Japan Diabetes Complications Study (JDCS). Diabetologia 2011 ; 54 : 2288-94.
P.240 掲載の参考文献
P.245 掲載の参考文献
4) Action to Control Cardiovascular Risk in Diabetes Study Group, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008 ; 358 : 2545-59.
5) ADVANCE Collaborative Group, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008 ; 358 : 2560-72.
7) Gastaldelli A, et al. Beta-cell dysfunction and glucose intolerance : results from the San Antonio metabolism (SAM) study. Diabetologia 2004 ; 47 : 31-9.
・ 志熊淳平, 小田原雅人. 2型糖尿病の厳格血糖管理と心血管病予防の効果をみる. Vascular Med 2011 ; 7 : 15-20.
P.252 掲載の参考文献
6) Kahn SE, et al ; ADOPT Study Group. Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT. Diabetes 2011 ; 60 : 1552-60.
7) Knowler WC, et al ; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002 ; 346 : 393-403.
12) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 ; 352 : 854-65.
P.261 掲載の参考文献
2) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 ; 352 : 854-65.
P.267 掲載の参考文献
P.274 掲載の参考文献
1) Action to Control Cardiovascular Risk in Diabetes Study Group, et al. Effect of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008 ; 358 : 2545-59.
2) ADVANCE Collaborative Group, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008 ; 358 : 2560-72.
4) ACCORD Study Group ; ACCORD Eye Study Group, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010 ; 363 : 233-44.
6) Zoungas S, et al ; ADVANCE Collaborative Group. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010 ; 363 : 1410-8.
P.279 掲載の参考文献
1) 日本高血圧学会高血圧治療ガイドライン作成委員会編. 高血圧治療ガイドライン 2009年版. ライフサイエンス出版 ; 2009.
3) Chaturvedi N, et al ; DIRECT Programme Study Group. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes : randomised, placebo-controlled trials. Lancet 2008 ; 372 : 1394-402.
4) Gade P, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003 ; 348 : 383-93.
P.285 掲載の参考文献
2) 上島弘嗣. NIPPON DATAからみた循環器疾患のエビデンス. 日本医事新報社 ; 2008.
4) 曽根博仁ほか. 日本から発信する血管病のEBM 第1回JDCS (Japan Diabetes complications Study). Vascular Medicine 2005 ; 1 : 86-94.
5) 清原裕. 地域住民中の糖尿病者における循環器疾患発症とその危険因子の関連久山町研究. 糖尿病合併症 2000 ; 14 : 80-4.
10) ACCORD Study Group, Ginsberg HN, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010 ; 362 : 1563-74.
11) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001 ; 285 : 2486-97.
P.291 掲載の参考文献
1) Gade P, et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria : the Steno type 2 randomised study. Lancet 1999 ; 353 : 617-22.
2) Gade P, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003 ; 348 : 383-93.
3) Gade P, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008 ; 358 : 580-91.
4) Gade P, Pedersen O. Intensive integrated therapy of type 2 diabetes : implications for long-term prognosis. Diabetes 2004 ; 53 (Suppl 3) : S39-47.
5) ACCORD Study Group, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010 ; 362 : 1563-74.
P.296 掲載の参考文献
1) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 ; 352 : 854-65.
4) ADVANCE Collaborative Group, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008 ; 358 : 2560-72.
6) Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008 ; 358 : 2545-59.
P.300 掲載の参考文献
4) Monami M, et al. Safety of dipeptidyl peptidase-4 inhibitors : a meta-analysis of randomized clinical trials. Curr Med Res Opin 2011 ; 27 (Suppl 3) : 57-64.
6) Iwasaki M, et al. Predicting efficacy of DPP-4 inhibitors in patients with type 2 diabetes : association of HbA1c reduction with serum eicosapentaenoic acid and docosahexaenoic acid levels. J Diabet Invest, in press.
P.304 掲載の参考文献
1) Glucose tolerance and mortality : comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology : Collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999 ; 354 : 617-21.
2) Nakagami T ; DECODA Study Group. Hyperglycaemia and mortality from all causes and from cardiovascular diseases in five populations of Asian origin. Diabetologia 2004 ; 47 : 385-94.
7) Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008 ; 358 : 2545-59.
8) ADVANCE Collaborative Group, Patel A, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008 ; 358 : 2560-72.

最近チェックした商品履歴

Loading...